April 27, 2018 09:40 AM EDT
R&D

Eye­ing block­buster mi­graine mar­ket, Al­ler­gan un­loads sec­ond set of pos­i­tive PhI­II re­sults for ubro­gepant

Brittany Meiling

Al­ler­gan $AGN rolled out its sec­ond wave of pos­i­tive Phase III da­ta for its oral mi­graine drug ubro­gepant, which nailed its end­points in the high­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times